**Torrent Pharmaceuticals Reports Lower-than-Expected Q3 Profit Amid Insulin Facility Closure**
India’s Torrent Pharmaceuticals announced a third-quarter profit that fell short of expectations, primarily due to the planned shutdown of its insulin manufacturing plant. The company, recognized for its calcium supplement Shelcal 500, reported a consolidated net profit of 5.03 billion rupees ($58.3 million) for the quarter ending December 31, reflecting a nearly 14% increase but missing analysts’ projections of 5.13 billion rupees, according to data from LSEG. Revenue increased by almost 3% to 28.09 billion rupees, yet it also fell below analysts’ estimates of 29.92 billion rupees.
While Indian pharmaceutical companies have experienced robust growth in domestic formulations, particularly in therapeutic areas such as cardiac, gastrointestinal, and anti-diabetes, Torrent Pharma faced challenges due to the August closure of its insulin facility and a 17% year-on-year depreciation of Brazil’s currency.
In contrast, competitor Granules India reported a decline in third-quarter profit due to pricing pressures in its primary European market, while Mankind Pharma also posted a profit that was lower than anticipated, impacted by a significant rise in expenses.
**Valuation Metrics for Selected Pharmaceutical Companies:**
– **Torrent Pharma**: PE 44.12, EV/EBITDA 25.46, Price/Revenue 6.81, Profit Growth 29.17%, Analyst Rating: Buy
– **Mankind Pharma**: PE 44.64, EV/EBITDA 26.53, Price/Revenue 6.99, Profit Growth 13.49%, Analyst Rating: Buy
– **Glenmark Pharma**: PE 24.96, EV/EBITDA 14.68, Price/Revenue 11.41, Profit Growth 63.98%, Analyst Rating: Buy
– **Sun Pharma**: PE 34.08, EV/EBITDA 25.52, Price/Revenue 6.30, Profit Growth 15.90%, Analyst Rating: Buy
*Note: Analyst ratings are standardized on a scale from Strong Buy to Strong Sell. The price-to-target ratio indicates whether the stock is trading above or below analysts’ mean price targets.*
